Marinomed Biotech AG publishes clinical data on efficacy of Carragelose lozenges against respiratory viruses including SARS-CoV-2 in the International Journal of General Medicine
September 09, 2021
Corporate News

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that positive clinical data on the antiviral efficacy of Carragelose-containing lozenges have been published in the peer-reviewed journal International Journal of General Medicine. The open access paper can be accessed on the journal’s website: The study was conducted in collaboration with Prof. Ulrich Schubert, Chair for Clinical Virology at the Friedrich-Alexander University Erlangen-Nuremberg, Germany and his team and adds to the increasing amount of evidence showing effective inhibition of SARS-CoV-2 by Carragelose.

The clinical study investigated whether sucking of one Carragelose-containing (10 mg) lozenge would lead to sufficient iota-carrageenan concentrations in the saliva of 31 healthy subjects to neutralize seven human respiratory viruses that cause common colds as well as COVID-19. The resulting iota-carrageenan concentrations are many times higher than the concentrations needed to inhibit 90 % of viral replication (IC90) of all tested viruses. This indicates that the lozenges are an appropriate measure to reduce infection and potentially preventing severe illness as well as transmission within a population. 

Full Press Release (Download)